While there are consequences of a 6-month episode of care under the Oncology Care Model (OCM), there will be trade-offs with any time window, explained Basit Chaudhry, MD, PhD, founder of Tuple Health.
While there are consequences of a 6-month episode of care under the Oncology Care Model (OCM), there will be trade-offs with any time window, explained Basit Chaudhry, MD, PhD, founder of Tuple Health.
Transcript
Are there any consequences of 6-month episodes of care under the Oncology Care Model?
One of the interesting things that’s happening substantively in terms of oncology itself and in terms of cancer, which has been a good thing to see, is that in many ways, cancers are fortunately taking on dimensions almost of chronic diseases. Patients are living with them much longer. This does create challenges on how to build a subspecialty payment model. So, there’s a lot of reasons why 6 months makes sense for an episode of care, but there’s also limitations to it. Just as an extreme example, say patients with myeloma. Fortunately, they’re living years with the disease. So, in looking at a 6-month snapshot, you really only get a snapshot; you’re not really getting the total picture of what’s happening in the course of the disease, which again, is a small miracle because this isn’t the way cancer was before.
So, it’s a relief and a great blessing for us as a society that this is now the case. But again, this does create challenges on how do you build a value-based subspecialty model, in turn, because you have to pick some time period if you want to do an episode-based model, and all of them have different trade-offs involved with it. So, I do think this is something we’ve been working on and thinking through in terms of in the future as we evolve value-based payment in oncology, what’s the right time frame, what’s the right trigger, when should you start looking at the services delivered, and related issues. I think there’s just going to be different trade-offs involved with the time window that you look at for these kinds of models.
Is there a better alternative to the 6-month episode?
I think that in terms of better, it’s a little difficult to say, because I think there’s just different trade-offs involved with the time windows that you look at. So, a lot of this is related to what are goals and objectives, what is the policy trying to create, what are you trying to structure, what are you trying to support or facilitate? For instance, are you trying to develop consistency of access to care and provider relationships or what exactly are you looking to do?
Rather than better, I think it’s really just in many ways different, and there’s just different trade-offs that are created in turn.
New TROPiCS-02 Data Back Sacituzumab Govitecan for Older Patients With Breast Cancer
December 9th 2023This phase 3 study investigated sacituzumab govitecan, a Trop-2–directed antibody-drug conjugate, vs treatment of physician’s choice in pretreated patients who have endocrine-resistant hormone receptor–positive/HER2-negative breast cancer, the most common form of breast cancer.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
New Insights on Breast Cancer Outcomes Among Sexual, Gender Minorities
December 7th 2023Despite there being a great demand for data collection on sexual orientation and gender identity in the cancer space, individuals who identify as a sexual and gender minority remain poorly represented.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Exagamglogene Autotemcel Meets End Points in Severe Sickle Cell Disease, β-Thalassemia
December 7th 2023Two posters set to be presented at the 65th American Society of Hematology Annual Meeting & Exposition met their primary and secondary end points regarding exagamglogene autotemcel therapy for sickle cell disease and β-thalassemia.
Read More
ASH 2023 to Highlight Options in Care for Blood Diseases—for Those Who Have Access
December 7th 2023The 65th American Society of Hematology (ASH) Annual Meeting & Exposition, which runs Friday through Tuesday in the San Diego Convention Center, will showcase the growing number of treatment choices in blood cancers and disorders.
Read More